SCHEMBL4170112

SCHEMBL4170112

CCOC(=O)Cn1cc(-c2ccco2)c(=O)[nH]c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.53
ALDH1A1 P00352 5/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.43
ADORA2B P29275 1/20 0.43
TDP1 Q9NUW8 2/20 0.43
LMNA P02545 2/20 0.43
MEN1 O00255 3/20 0.42
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.42
HPGD P15428 2/20 0.42
USP2 O75604 1/20 0.42
GAA P10253 1/20 0.42
P2RY2 P41231 1/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
HTT P42858 1/20 0.39
PIN1 Q13526 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4174262 0.84 P2RY2 (0.44) KMT2AALDH1A1TDP1MEN1P2RY2
SCHEMBL4162994 0.76 KMT2A (0.53) KMT2AALDH1A1TSHRTDP1LMNA
SCHEMBL4174300 0.75 ALDH1A1 (0.47) KMT2AALDH1A1TSHRMAPK1ADORA2B
SCHEMBL3516690 0.75 KMT2A (0.68) KMT2AMAPK1LMNAHPGD
SCHEMBL23211184 0.72 KMT2A (0.64) KMT2AALDH1A1MAPK1TDP1LMNA
SCHEMBL4160782 0.72 KMT2A (0.64) KMT2AALDH1A1TDP1LMNAPIN1
SCHEMBL7830622 0.71 PIK3R1 (0.44) KMT2AALDH1A1TSHRMEN1P2RY2
SCHEMBL4157745 0.71 ALDH1A1 (0.54) KMT2AALDH1A1TSHRMAPK1MEN1
SCHEMBL17622450 0.69 KMT2A (1.00) KMT2AALDH1A1TDP1LMNAMEN1
SCHEMBL17622452 0.69 KMT2A (0.59) KMT2AALDH1A1TDP1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
WO-2007122634-A2 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2007-11-01 WO disclosed
WO-2007122634-A2 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS TK1, LCK, FYN KMT2A 2499/4885ALDH1A1 1813/4885TSHR 2530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.